Literature DB >> 3258901

Distribution of pentamidine in patients with AIDS.

H Donnelly1, E M Bernard, H Rothkotter, J W Gold, D Armstrong.   

Abstract

We used a bioassay to measure pentamidine concentrations in autopsy specimens from 22 patients with AIDS. Patients received pentamidine isethionate (approximately 4 mg/kg per day) parenterally for Pneumocystis carinii pneumonia; one received monthly prophylaxis. We found that lung levels of 30 micrograms/g were achieved only after the fifth dose; tissue accumulation was usually greater in the liver, kidney, adrenal, and spleen than in the lung; detectable levels were present in some tissues as late as one year after the last dose; and low but detectable levels were present in the brain of six of 17 patients. Two patients had no detectable lung levels after two days of therapy; one had a level of 17.5 micrograms/g after four doses, and two had levels of 30 micrograms/g after five doses. A more rapid and effective method of delivery, such as aerosol, should achieve higher concentrations earlier. Because pentamidine persists in lung tissue over days to weeks, daily administration may not be necessary.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258901     DOI: 10.1093/infdis/157.5.985

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Adult respiratory distress syndrome complicating Pneumocystis carinii pneumonia.

Authors:  A Scoular; J Moxham; S B Lucas; R F Miller
Journal:  Genitourin Med       Date:  1991-06

Review 2.  Problems and pitfalls in the assay of pentamidine. Implications for clinical use.

Authors:  B J Berger; L Henry; J E Hall; R R Tidwell
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Aids and the lung. 6-- Management of respiratory failure in patients with the acquired immune deficiency syndrome and Pneumocystis carinii pneumonia.

Authors:  R F Miller; D M Mitchell
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

Review 4.  Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia.

Authors:  J P Monk; P Benfield
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 5.  Pentamidine. A risk-benefit analysis.

Authors:  B Wispelwey; R Pearson
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

6.  In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.

Authors:  Javier Afeltra; Eric Dannaoui; Jacques F G M Meis; Juan L Rodriguez-Tudela; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness.

Authors:  U Bronner; L L Gustafsson; F Doua; O Ericsson; T Miézan; M Rais; L Rombo
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 8.  Pharmacokinetic justification of antiprotozoal therapy. A US perspective.

Authors:  J D Berman; L Fleckenstein
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 9.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  Structure and inhibition of human diamine oxidase.

Authors:  Aaron P McGrath; Kimberly M Hilmer; Charles A Collyer; Eric M Shepard; Bradley O Elmore; Doreen E Brown; David M Dooley; J Mitchell Guss
Journal:  Biochemistry       Date:  2009-10-20       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.